

Global Late Stage Chronic Kidney Disease Drugs Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/G4D16B54E1C9EN.html>

Date: August 2020

Pages: 94

Price: US\$ 3,900.00 (Single User License)

ID: G4D16B54E1C9EN

Abstracts

This report focuses on the global Late Stage Chronic Kidney Disease Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Late Stage Chronic Kidney Disease Drugs development in North America, Europe and Asia-Pacific.

The key players covered in this study

AbbVie

Amgen

Ardelyx

AstraZeneca

Deltanoid

Akebia Therapeutics

Kyowa Hakko Kirin

OPKO Health

Vifor Pharma

Sanofi

Shield Therapeutics

Shire

Spectrum

ZS Pharma

Market segment by Type, the product can be split into

Calcimimetics

Vitamin D Sterols

Potassium Binders

Others

Market segment by Application, split into

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Market segment by Regions/Countries, this report covers

North America

Europe

Asia-Pacific

The study objectives of this report are:

To analyze global Late Stage Chronic Kidney Disease Drugs status, future forecast, growth opportunity, key market and key players.

To present the Late Stage Chronic Kidney Disease Drugs development in North America, Europe and Asia-Pacific.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Late Stage Chronic Kidney Disease Drugs are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Late Stage Chronic Kidney Disease Drugs Revenue

1.4 Market Analysis by Type

1.4.1 Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Calcimimetics

1.4.3 Vitamin D Sterols

1.4.4 Potassium Binders

1.4.5 Others

1.5 Market by Application

1.5.1 Global Late Stage Chronic Kidney Disease Drugs Market Share by Application: 2020 VS 2026

1.5.2 Hospital Pharmacies

1.5.3 Online Pharmacies

1.5.4 Retail Pharmacies

1.6 Coronavirus Disease 2019 (Covid-19): Late Stage Chronic Kidney Disease Drugs Industry Impact

1.6.1 How the Covid-19 is Affecting the Late Stage Chronic Kidney Disease Drugs Industry

1.6.1.1 Late Stage Chronic Kidney Disease Drugs Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Late Stage Chronic Kidney Disease Drugs Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Late Stage Chronic Kidney Disease Drugs Players to Combat Covid-19 Impact

1.7 Study Objectives

1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

- 2.1 Late Stage Chronic Kidney Disease Drugs Market Perspective (2015-2026)
- 2.2 Late Stage Chronic Kidney Disease Drugs Growth Trends by Regions
 - 2.2.1 Late Stage Chronic Kidney Disease Drugs Market Size by Regions: 2015 VS 2020 VS 2026
 - 2.2.2 Late Stage Chronic Kidney Disease Drugs Historic Market Share by Regions (2015-2020)
 - 2.2.3 Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
 - 2.3.1 Market Top Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Challenges
 - 2.3.4 Porter's Five Forces Analysis
 - 2.3.5 Late Stage Chronic Kidney Disease Drugs Market Growth Strategy
 - 2.3.6 Primary Interviews with Key Late Stage Chronic Kidney Disease Drugs Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

- 3.1 Global Top Late Stage Chronic Kidney Disease Drugs Players by Market Size
 - 3.1.1 Global Top Late Stage Chronic Kidney Disease Drugs Players by Revenue (2015-2020)
 - 3.1.2 Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Players (2015-2020)
 - 3.1.3 Global Late Stage Chronic Kidney Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global Late Stage Chronic Kidney Disease Drugs Market Concentration Ratio
 - 3.2.1 Global Late Stage Chronic Kidney Disease Drugs Market Concentration Ratio (CR5 and HHI)
 - 3.2.2 Global Top 10 and Top 5 Companies by Late Stage Chronic Kidney Disease Drugs Revenue in 2019
- 3.3 Late Stage Chronic Kidney Disease Drugs Key Players Head office and Area Served
- 3.4 Key Players Late Stage Chronic Kidney Disease Drugs Product Solution and Service
- 3.5 Date of Enter into Late Stage Chronic Kidney Disease Drugs Market
- 3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Late Stage Chronic Kidney Disease Drugs Historic Market Size by Type (2015-2020)

4.2 Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Type (2021-2026)

5 LATE STAGE CHRONIC KIDNEY DISEASE DRUGS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020)

5.2 Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Late Stage Chronic Kidney Disease Drugs Market Size (2015-2020)

6.2 Late Stage Chronic Kidney Disease Drugs Key Players in North America (2019-2020)

6.3 North America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020)

6.4 North America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size (2015-2020)

7.2 Late Stage Chronic Kidney Disease Drugs Key Players in Europe (2019-2020)

7.3 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020)

7.4 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020)

8 ASIA-PACIFIC

8.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size (2015-2020)

8.2 Late Stage Chronic Kidney Disease Drugs Key Players in Asia-Pacific (2019-2020)

8.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020)

8.4 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application
(2015-2020)
(2015-2020)
(2015-2020)

9 KEY PLAYERS PROFILES

9.1 AbbVie

9.1.1 AbbVie Company Details

9.1.2 AbbVie Business Overview and Its Total Revenue

9.1.3 AbbVie Late Stage Chronic Kidney Disease Drugs Introduction

9.1.4 AbbVie Revenue in Late Stage Chronic Kidney Disease Drugs Business
(2015-2020))

9.1.5 AbbVie Recent Development

9.2 Amgen

9.2.1 Amgen Company Details

9.2.2 Amgen Business Overview and Its Total Revenue

9.2.3 Amgen Late Stage Chronic Kidney Disease Drugs Introduction

9.2.4 Amgen Revenue in Late Stage Chronic Kidney Disease Drugs Business
(2015-2020)

9.2.5 Amgen Recent Development

9.3 Ardelyx

9.3.1 Ardelyx Company Details

9.3.2 Ardelyx Business Overview and Its Total Revenue

9.3.3 Ardelyx Late Stage Chronic Kidney Disease Drugs Introduction

9.3.4 Ardelyx Revenue in Late Stage Chronic Kidney Disease Drugs Business
(2015-2020)

9.3.5 Ardelyx Recent Development

9.4 AstraZeneca

9.4.1 AstraZeneca Company Details

9.4.2 AstraZeneca Business Overview and Its Total Revenue

9.4.3 AstraZeneca Late Stage Chronic Kidney Disease Drugs Introduction

9.4.4 AstraZeneca Revenue in Late Stage Chronic Kidney Disease Drugs Business
(2015-2020)

9.4.5 AstraZeneca Recent Development

9.5 Deltanoid

9.5.1 Deltanoid Company Details

9.5.2 Deltanoid Business Overview and Its Total Revenue

9.5.3 Deltanoid Late Stage Chronic Kidney Disease Drugs Introduction

9.5.4 Deltanoid Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)

9.5.5 Deltanoid Recent Development

9.6 Akebia Therapeutics

9.6.1 Akebia Therapeutics Company Details

9.6.2 Akebia Therapeutics Business Overview and Its Total Revenue

9.6.3 Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Introduction

9.6.4 Akebia Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)

9.6.5 Akebia Therapeutics Recent Development

9.7 Kyowa Hakko Kirin

9.7.1 Kyowa Hakko Kirin Company Details

9.7.2 Kyowa Hakko Kirin Business Overview and Its Total Revenue

9.7.3 Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Introduction

9.7.4 Kyowa Hakko Kirin Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)

9.7.5 Kyowa Hakko Kirin Recent Development

9.8 OPKO Health

9.8.1 OPKO Health Company Details

9.8.2 OPKO Health Business Overview and Its Total Revenue

9.8.3 OPKO Health Late Stage Chronic Kidney Disease Drugs Introduction

9.8.4 OPKO Health Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)

9.8.5 OPKO Health Recent Development

9.9 Vifor Pharma

9.9.1 Vifor Pharma Company Details

9.9.2 Vifor Pharma Business Overview and Its Total Revenue

9.9.3 Vifor Pharma Late Stage Chronic Kidney Disease Drugs Introduction

9.9.4 Vifor Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)

9.9.5 Vifor Pharma Recent Development

9.10 Sanofi

9.10.1 Sanofi Company Details

9.10.2 Sanofi Business Overview and Its Total Revenue

9.10.3 Sanofi Late Stage Chronic Kidney Disease Drugs Introduction

9.10.4 Sanofi Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)

9.10.5 Sanofi Recent Development

9.11 Shield Therapeutics

- 10.11.1 Shield Therapeutics Company Details
- 10.11.2 Shield Therapeutics Business Overview and Its Total Revenue
- 10.11.3 Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Introduction
- 10.11.4 Shield Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- 10.11.5 Shield Therapeutics Recent Development
- 9.12 Shire
 - 10.12.1 Shire Company Details
 - 10.12.2 Shire Business Overview and Its Total Revenue
 - 10.12.3 Shire Late Stage Chronic Kidney Disease Drugs Introduction
 - 10.12.4 Shire Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
 - 10.12.5 Shire Recent Development
- 9.13 Spectrum
 - 10.13.1 Spectrum Company Details
 - 10.13.2 Spectrum Business Overview and Its Total Revenue
 - 10.13.3 Spectrum Late Stage Chronic Kidney Disease Drugs Introduction
 - 10.13.4 Spectrum Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
 - 10.13.5 Spectrum Recent Development
- 9.14 ZS Pharma
 - 10.14.1 ZS Pharma Company Details
 - 10.14.2 ZS Pharma Business Overview and Its Total Revenue
 - 10.14.3 ZS Pharma Late Stage Chronic Kidney Disease Drugs Introduction
 - 10.14.4 ZS Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
 - 10.14.5 ZS Pharma Recent Development

10 ANALYST'S VIEWPOINTS/CONCLUSIONS

11 APPENDIX

- 11.1 Research Methodology
 - 11.1.1 Methodology/Research Approach
 - 11.1.2 Data Source
- 11.2 Disclaimer
- 11.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Late Stage Chronic Kidney Disease Drugs Key Market Segments

Table 2. Key Players Covered: Ranking by Late Stage Chronic Kidney Disease Drugs Revenue

Table 3. Ranking of Global Top Late Stage Chronic Kidney Disease Drugs Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Calcimimetics

Table 6. Key Players of Vitamin D Sterols

Table 7. Key Players of Potassium Binders

Table 8. Key Players of Others

Table 9. COVID-19 Impact Global Market: (Four Late Stage Chronic Kidney Disease Drugs Market Size Forecast Scenarios)

Table 10. Opportunities and Trends for Late Stage Chronic Kidney Disease Drugs Players in the COVID-19 Landscape

Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 12. Key Regions/Countries Measures against Covid-19 Impact

Table 13. Proposal for Late Stage Chronic Kidney Disease Drugs Players to Combat Covid-19 Impact

Table 14. Global Late Stage Chronic Kidney Disease Drugs Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 15. Global Late Stage Chronic Kidney Disease Drugs Market Size by Regions (US\$ Million): 2020 VS 2026

Table 16. Global Late Stage Chronic Kidney Disease Drugs Market Size by Regions (2015-2020) (US\$ Million)

Table 17. Global Late Stage Chronic Kidney Disease Drugs Market Share by Regions (2015-2020)

Table 18. Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 19. Global Late Stage Chronic Kidney Disease Drugs Market Share by Regions (2021-2026)

Table 20. Market Top Trends

Table 21. Key Drivers: Impact Analysis

Table 22. Key Challenges

Table 23. Late Stage Chronic Kidney Disease Drugs Market Growth Strategy

- Table 24. Main Points Interviewed from Key Late Stage Chronic Kidney Disease Drugs Players
- Table 25. Global Late Stage Chronic Kidney Disease Drugs Revenue by Players (2015-2020) (Million US\$)
- Table 26. Global Late Stage Chronic Kidney Disease Drugs Market Share by Players (2015-2020)
- Table 27. Global Top Late Stage Chronic Kidney Disease Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Late Stage Chronic Kidney Disease Drugs as of 2019)
- Table 28. Global Late Stage Chronic Kidney Disease Drugs by Players Market Concentration Ratio (CR5 and HHI)
- Table 29. Key Players Headquarters and Area Served
- Table 30. Key Players Late Stage Chronic Kidney Disease Drugs Product Solution and Service
- Table 31. Date of Enter into Late Stage Chronic Kidney Disease Drugs Market
- Table 32. Mergers & Acquisitions, Expansion Plans
- Table 33. Global Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020) (Million US\$)
- Table 34. Global Late Stage Chronic Kidney Disease Drugs Market Size Share by Type (2015-2020)
- Table 35. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Type (2021-2026)
- Table 36. Global Late Stage Chronic Kidney Disease Drugs Market Size Share by Application (2015-2020)
- Table 37. Global Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020) (Million US\$)
- Table 38. Global Late Stage Chronic Kidney Disease Drugs Market Size Share by Application (2021-2026)
- Table 39. North America Key Players Late Stage Chronic Kidney Disease Drugs Revenue (2019-2020) (Million US\$)
- Table 40. North America Key Players Late Stage Chronic Kidney Disease Drugs Market Share (2019-2020)
- Table 41. North America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020) (Million US\$)
- Table 42. North America Late Stage Chronic Kidney Disease Drugs Market Share by Type (2015-2020)
- Table 43. North America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020) (Million US\$)
- Table 44. North America Late Stage Chronic Kidney Disease Drugs Market Share by

Application (2015-2020)

Table 45. Europe Key Players Late Stage Chronic Kidney Disease Drugs Revenue (2019-2020) (Million US\$)

Table 46. Europe Key Players Late Stage Chronic Kidney Disease Drugs Market Share (2019-2020)

Table 47. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020) (Million US\$)

Table 48. Europe Late Stage Chronic Kidney Disease Drugs Market Share by Type (2015-2020)

Table 49. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020) (Million US\$)

Table 50. Europe Late Stage Chronic Kidney Disease Drugs Market Share by Application (2015-2020)

Table 51. Asia-Pacific Key Players Late Stage Chronic Kidney Disease Drugs Revenue (2019-2020) (Million US\$)

Table 52. Asia-Pacific Key Players Late Stage Chronic Kidney Disease Drugs Market Share (2019-2020)

Table 53. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020) (Million US\$)

Table 54. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Share by Type (2015-2020)

Table 55. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020) (Million US\$)

Table 56. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Share by Application (2015-2020)

Table 57. AbbVie Company Details

Table 58. AbbVie Business Overview

Table 59. AbbVie Product

Table 60. AbbVie Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 61. AbbVie Recent Development

Table 62. Amgen Company Details

Table 63. Amgen Business Overview

Table 64. Amgen Product

Table 65. Amgen Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 66. Amgen Recent Development

Table 67. Ardelyx Company Details

Table 68. Ardelyx Business Overview

Table 69. Ardelyx Product

Table 70. Ardelyx Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 71. Ardelyx Recent Development

Table 72. AstraZeneca Company Details

Table 73. AstraZeneca Business Overview

Table 74. AstraZeneca Product

Table 75. AstraZeneca Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 76. AstraZeneca Recent Development

Table 77. Deltanoid Company Details

Table 78. Deltanoid Business Overview

Table 79. Deltanoid Product

Table 80. Deltanoid Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 81. Deltanoid Recent Development

Table 82. Akebia Therapeutics Company Details

Table 83. Akebia Therapeutics Business Overview

Table 84. Akebia Therapeutics Product

Table 85. Akebia Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 86. Akebia Therapeutics Recent Development

Table 87. Kyowa Hakko Kirin Company Details

Table 88. Kyowa Hakko Kirin Business Overview

Table 89. Kyowa Hakko Kirin Product

Table 90. Kyowa Hakko Kirin Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 91. Kyowa Hakko Kirin Recent Development

Table 92. OPKO Health Business Overview

Table 93. OPKO Health Product

Table 94. OPKO Health Company Details

Table 95. OPKO Health Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 96. OPKO Health Recent Development

Table 97. Vifor Pharma Company Details

Table 98. Vifor Pharma Business Overview

Table 99. Vifor Pharma Product

Table 100. Vifor Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 101. Vifor Pharma Recent Development

Table 102. Sanofi Company Details

Table 103. Sanofi Business Overview

Table 104. Sanofi Product

Table 105. Sanofi Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 106. Sanofi Recent Development

Table 107. Shield Therapeutics Company Details

Table 108. Shield Therapeutics Business Overview

Table 109. Shield Therapeutics Product

Table 110. Shield Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 111. Shield Therapeutics Recent Development

Table 112. Shire Company Details

Table 113. Shire Business Overview

Table 114. Shire Product

Table 115. Shire Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 116. Shire Recent Development

Table 117. Spectrum Company Details

Table 118. Spectrum Business Overview

Table 119. Spectrum Product

Table 120. Spectrum Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 121. Spectrum Recent Development

Table 122. ZS Pharma Company Details

Table 123. ZS Pharma Business Overview

Table 124. ZS Pharma Product

Table 125. ZS Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US\$)

Table 126. ZS Pharma Recent Development

Table 127. Research Programs/Design for This Report

Table 128. Key Data Information from Secondary Sources

Table 129. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Late Stage Chronic Kidney Disease Drugs Market Share by Type: 2020 VS 2026

Figure 2. Calcimimetics Features

Figure 3. Vitamin D Sterols Features

Figure 4. Potassium Binders Features

Figure 5. Others Features

Figure 6. Global Late Stage Chronic Kidney Disease Drugs Market Share by Application: 2020 VS 2026

Figure 7. Hospital Pharmacies Case Studies

Figure 8. Online Pharmacies Case Studies

Figure 9. Retail Pharmacies Case Studies

Figure 10. Late Stage Chronic Kidney Disease Drugs Report Years Considered

Figure 11. Global Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth 2015-2026 (US\$ Million)

Figure 12. Global Late Stage Chronic Kidney Disease Drugs Market Share by Regions: 2020 VS 2026

Figure 13. Global Late Stage Chronic Kidney Disease Drugs Market Share by Regions (2021-2026)

Figure 14. Porter's Five Forces Analysis

Figure 15. Global Late Stage Chronic Kidney Disease Drugs Market Share by Players in 2019

Figure 16. Global Top Late Stage Chronic Kidney Disease Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Late Stage Chronic Kidney Disease Drugs as of 2019)

Figure 17. The Top 10 and 5 Players Market Share by Late Stage Chronic Kidney Disease Drugs Revenue in 2019

Figure 18. North America Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 19. Europe Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 20. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2015-2020) (Million US\$)

Figure 21. AbbVie Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 22. AbbVie Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)

- Figure 23. Amgen Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 24. Amgen Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- Figure 25. Ardelyx Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 26. Ardelyx Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- Figure 27. AstraZeneca Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 28. AstraZeneca Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- Figure 29. Deltanoid Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 30. Deltanoid Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- Figure 31. Akebia Therapeutics Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 32. Akebia Therapeutics Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- Figure 33. Kyowa Hakko Kirin Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 34. Kyowa Hakko Kirin Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- Figure 35. OPKO Health Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 36. OPKO Health Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- Figure 37. Vifor Pharma Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 38. Vifor Pharma Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- Figure 39. Sanofi Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 40. Sanofi Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- Figure 41. Shield Therapeutics Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 42. Shield Therapeutics Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- Figure 43. Shire Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 44. Shire Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- Figure 45. Spectrum Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 46. Spectrum Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
- Figure 47. ZS Pharma Total Revenue (US\$ Million): 2019 Compared with 2018
- Figure 48. ZS Pharma Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)

Figure 49. Bottom-up and Top-down Approaches for This Report

Figure 50. Data Triangulation

Figure 51. Key Executives Interviewed

I would like to order

Product name: Global Late Stage Chronic Kidney Disease Drugs Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/G4D16B54E1C9EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4D16B54E1C9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

